Educational Bus Tour To Tell Patients How To Simply And Safely Check Blood Coagulation Levels From Home, UK
April 4th, 2008 | by admin |There are more than a million people in the UK on long-term warfarini and this number is set to increase by 10% year-on-year, due to the ageing populationii.
Roche Diagnostics, a pioneer in the development of monitoring systems for anticoagulation, supported by the patient group AntiCoagulation Europe (ACE), is conducting an educational bus tour across the UK and Ireland to raise awareness of the potential benefits of patient self-testing. The bus will be stopping at 24 locations across the UK and Ireland and is open to the public free of charge.
The CoaguNation Bus Tour will provide long-term warfarin patients, and their family and friends, with an opportunity to learn more about the practical aspects and potential benefits of anticoagulation self-testing. This will include information on how to simply and safely check their own blood coagulation levels from home, providing more freedom for the patient.
A local anticoagulation nurse will be on board to give practical advice and educational demonstrations on how to use self-testing devices. The nurse will also be able to answer any questions which patients, their family or friends may have regarding warfarin medication and self-testing. There will also be a local member of AntiCoagulation Europe on board to provide first hand experience of self-testing, as well as a number of educational patient support materials which visitors can take away from the event.
The CoaguNation Bus Tour will stop at 24 locations in the UK and Ireland on various dates from May to July 2008. Please help to spread the word and inform your warfarin patients of the UK-wide CoaguNation Bus Tour:
For more information and a full list of dates and locations / venues call the CoaguChek helpline free on 0808 1007666 or visit http://www.onwarfarin.co.uk.
About Roche and the Roche Diagnostics Division
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people.
Roche’s Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our website at www.roche.com.
All trademarks used or mentioned in this release are legally protected by law.
i Based on an extrapolation of 2004 figures presented in Gardiner et al. Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring. British Journal of Haematology. 2004; 128: 242-247.
ii Fitzmaurice DA et al. Self-management of oral anticoagulation: randomised trial. BMJ. 2007; 331(7524): 1057.
http://www.roche.com
Stumble it!